ProQR Therapeutics (PRQR)
(Real Time Quote from BATS)
$2.03 USD
+0.09 (4.64%)
Updated Apr 29, 2024 01:30 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Balance Sheet
Fiscal Year End for ProQR Therapeutics NV falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 129 | 100 | 222 | 87 | 125 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 2 | 63 | 5 | 5 | 3 |
Total Current Assets | 131 | 163 | 227 | 91 | 128 |
Net Property & Equipment | 18 | 17 | 21 | 21 | 3 |
Investments & Advances | 0 | 1 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 149 | 181 | 248 | 113 | 132 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 0 | 0 | 0 | 1 |
Current Portion Long-Term Debt | 0 | 3 | 6 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 34 | 18 | 25 | 9 | 11 |
Total Current Liabilities | 37 | 22 | 33 | 12 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 48 | 71 | 17 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 5 | 5 | 47 | 18 | 14 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 104 | 112 | 114 | 48 | 27 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 4 | 4 | 4 | 2 | 2 |
Capital Surplus | 447 | 435 | 471 | 330 | 322 |
Retained Earnings | -434 | -401 | -376 | -294 | -237 |
Other Equity | 28 | 31 | 35 | 27 | 18 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 45 | 69 | 134 | 65 | 105 |
Total Liabilities & Shareholder's Equity | 149 | 181 | 248 | 113 | 132 |
Total Common Equity | 45 | 69 | 134 | 65 | 105 |
Shares Outstanding | 81.30 | 80.80 | 71.20 | 50.20 | 49.70 |
Book Value Per Share | 0.55 | 0.85 | 1.88 | 1.29 | 2.11 |
Fiscal Year End for ProQR Therapeutics NV falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 129 | 131 | 140 | 149 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 2 | 5 | 3 | 3 |
Total Current Assets | NA | 131 | 136 | 143 | 152 |
Net Property & Equipment | NA | 18 | 19 | 18 | 17 |
Investments & Advances | NA | 0 | 0 | 1 | 1 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 149 | 155 | 161 | 170 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 2 | 0 | 0 | 0 |
Current Portion Long-Term Debt | NA | 0 | 3 | 3 | 3 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 0 | 0 | 0 | 0 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 34 | 25 | 20 | 14 |
Total Current Liabilities | NA | 37 | 29 | 25 | 18 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 48 | 56 | 61 | 70 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 5 | 3 | 4 | 4 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 104 | 104 | 105 | 107 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 4 | 4 | 4 | 4 |
Capital Surplus | NA | 447 | 449 | 450 | 443 |
Retained Earnings | NA | -434 | -431 | -427 | -412 |
Other Equity | NA | 28 | 28 | 30 | 29 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 45 | 50 | 56 | 63 |
Total Liabilities & Shareholder's Equity | NA | 149 | 155 | 161 | 170 |
Total Common Equity | 0 | 45 | 50 | 56 | 63 |
Shares Outstanding | 81.30 | 81.30 | 80.80 | 80.80 | 80.80 |
Book Value Per Share | 0.00 | 0.55 | 0.62 | 0.70 | 0.78 |